MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer Clinical Trial
Official title:
A Phase II Trial of AK104(PD-1 and CTLA-4 Bispecific Antibody) in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer During the Perioperative Period
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative period.Eligible patients will receive AK104 for three cycles before surgery and at most 6 months after surgery. The primary endpoint is the pathological complete response rate.
n/a